الفهرس 
cover EnglishOnly 14 pages are availabe for public view
 |  | from | 171 |  |  |
| | | from | 171 | | |
Abstract
Breast cancer is the most common cancer and the highest cause of cancer mortality in women worldwide. It is increasingly reported in young premenopausal women in Egypt. Adjuvant chemotherapy improves survival; however, it has a unique consequence of ovarian failure in premenopausal patients. Objective: This study’s aim was to find the incidence of chemotherapy-induced ovarian failure and reversible amenorrhea in premenopausal non-metastatic breast cancer patients. Method: This study follows premenopausal breast cancer patients receiving chemotherapy refered to Medical Oncology Clinic in National Cancer Institute. It included all patients with early breast cancer with at least a minimum follow up of one year after last cycle of adjuvant chemotherapy and patients were asked about their menstrual history. Results: The study included 100 Egyptian female patients. The mean age of the subjects was 45 years. Of the patients, 56 were amenorrheic at completion of study and 44 regained menstruations, on average after 8 (range 2–24) months post-chemotherapy. Age was the only statistically significant risk factor. Conclusion: This study found a high incidence of CIOF, with a relatively low rate of reversible amenorrhea. Premenopausal patients should be counselled prior to treatment and education and support provided. Chemotherapy is a crucial part of treatment for breast cancer and has been shown to improve survival. However, it does come with certain consequences such as ovarian failure, which may be temporary or permanent. This has implications for fertility and the premature onset of menopause, which consequently may affect the patient’s decisions regarding treatment regime and compliance with treatment. Key Words: Breast cancer, reversible amenorrhea, chemotherapy induced ovarian failure, premenopause.